anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Survival of patients undergoing therapy with FOLFIRI + cetuximab seems to be related to the ability of this treatment to induce a rapid reduction in tumor mass. In the retrospective analyses of the FIRE-3 trial ETS was significantly associated with PFS and OS, suggesting that ETS reflects the existence of a selected population of patients highly sensitive to cetuximab. This permits the assumption that, once this goal has been achieved, further exposure to combined antineoplastic treatment (cytotoxic drugs and targeted therapy) may not result in improvement or preservation of the result, but only in an increase of side effects that will be additional to unavoidable disease progression. In addition, the heavy exposure to cytotoxic antineoplastic treatments may lead to bone marrow toxicity, hepatic and renal function decreases that could compromise the sequential treatment plan, negatively affecting OS. With the availability of an effective treatment such as cetuximab in monotherapy4 without major side effects on blood counts and liver and kidney function, the use of this treatment alone after achievement of the deepest clinical response could be a viable strategy to achieve a good control of the disease, limiting side effects. As shown in several studies designed to understand the most effective treatment sequence in colorectal carcinoma, the most important factor that influences the overall survival is the possibility to administer more lines of effective therapy. As a consequence, a de-intensifying strategy in a subgroup of highly selected RAS and BRAF WT population might segregate a group of patients with the largest potential for fast-primary treatment. Joining the best induction treatment with the expression of patients capability to undergo additional lines of antineoplastic therapy may be the way to optimize the continuum of care.

Recently, several mechanisms of resistance to anti-EGFR therapy have been described, but until now none may used early in order to support the treatment choice.Moreover, assessment of secondary resistance requires further tissue samples and often it is not really feasible. Therefore, a prospective multiple gene mutation analysis could meet the need of characterizing primary resistance, whereas liquid biopsy might help to recognize resistance occurring early during treatment by means of a simple and repeatable assay. Based on all these considerations, the investigators designed a strategy study: a phase III randomized two arm study with FOLFIRI + cetuximab until disease progression compared to FOLFIRI + cetuximab for 8 cycles followed by cetuximab alone until disease progression in the first line treatment of patients with RAS and BRAF WT metastatic colorectal cancer combined with a prospective multiple gene mutation analysis of both tumor tissue and blood.
Simulation CTs of up to ten patients with bulky (\>6cm) tumors will be selected. This will be used for optimization of contouring and planning strategy.
Because clinical trials are conducted under widely varying conditions and using a wide range of doses, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

The safety of VISTOGARD was assessed in 135 patients (median age 59 years, 56% male) treated in 2 single-arm, open-label, multi-center trials. VISTOGARD was administered at 10 grams orally every 6 hours for 20 doses or at a body surface area adjusted dosage of 6.2 grams/m2/dose for 20 doses in four patients between 1 and 7 years of age. The median duration of exposure was 4.8 days, with a median of 20 doses (range 1 to 23). VISTOGARD was discontinued for adverse reactions in two (1.4%) patients. Serious adverse reactions and Grade ≥3 adverse reactions were seen in one patient receiving VISTOGARD (Grade 3 nausea and vomiting). Table 2 summarizes the adverse reactions that occurred in greater than 2% of patients in Studies 1 and 2 combined.
PURPOSE: To obtain a simply usable and curable composition for a denture base, capable of maintaining a rice caky state for a long period and preparable in a short time by premixing a high-molecular weight polymer powder with a polymerizable monomer which is a liquid component. CONSTITUTION: This curable composition for a denture base contains (A) a high- molecular weight polymer (a terpolymer comprising 5-35mol% methyl methacrylate, 40-80mol% butadiene and 15-40mol% styrene is especially preferred) and (B) a polymerizable monomer (e.g. methyl acrylate) which is a liquid component. The pressurized flow degree is 10-60mm and a change with time in the pressurized flow degree after the passage of 24hr from the preparation is preferably <=10%. Particles having 10-100μm average particle diameter are preferably used as the high-molecular weight polymer. The composition preferably contains 15-65 pts.wt. component (A) based on 100 pts.wt. total amount of the components (A) and (B) or may further contain 0.01-20 pts.wt. polymerization initiator based on 100 pts.wt. total amount of the components (A) and (B).  Furthermore, the composition may contain 1-15 pts.wt. filler (preferably having 10-100μm average particle diameter) comprising a material different from the component (A) based on 100 pts.wt. total amount of the components (A) and (B).
The purpose of the Registry for Systemic Eczema Therapies (RESET) registry is to serve as a database and biospecimen repository of patients with pediatric-onset atopic dermatitis (AD), also known as eczema. This registry seeks to enroll patients with AD who have used or will initiate any systemic treatment(s) for AD. Such a registry will allow investigators to identify patients who are potentially eligible for AD research protocols, including observational studies or clinical trials. The registry will also prospectively collect data that would then serve as a resource for studying a variety of questions surrounding systemic therapy use in patients with AD, for example comparing the effectiveness of treatments or examining treatment effects on patient-reported outcomes. Moreover, the registry would permit safety monitoring of systemic AD medications, as it would include both patients receiving traditional systemic agents with well-known side effect profiles and patients receiving more novel systemic agents with under-characterized side effect profiles. Finally, this registry would allow for the identification of patients with moderate-to-severe AD who may be eligible to receive and benefit from the rapidly expanding number of U.S. Food and Drug Administration (FDA)-approved systemic therapies for AD.
1. A method of shelf preservation of biologically active materials by drying comprising the step of subjecting a solution, dispersion or suspension containing a biologically active agent to a vacuum corresponding to the remaining hydrostatic pressure lower than 24 Torr sufficient to cause said solution, dispersion or suspension to boil such that said boiled solution, dispersion or suspension is dried to yield a mechanically stable foam during boiling. 2. The method according to claim 1 wherein said hydrostatic pressure is between 0 and 7.6 Torr. 3. The method according to claim 1 wherein prior to the step of subjecting said solution, dispersion or suspension to a high vacuum said solution, dispersion or suspension is dehydrated or concentrated by evaporation from liquid state at a low vacuum corresponding to the remaining hydrostatic pressure higher than 7.6 Torr or by evaporation from partially frozen state or by concentration by reverse osmosis or other membrane technologies to reduce the time during which said high vacuum must be applied and to increase the viscosity of said solution, dispersion or suspension before boiling under high vacuum. 4. The method according to claim 1 wherein a secondary drying process is carried out by applying one of a vacuum or dry air to said stable foam at elevated temperature. 5. The method according to claim 4 wherein after the secondary drying procedure the foam is cooled to a temperature that is lower than the glass transition temperature of the dried foam. 6. The method according to claim 5 wherein a surfactant is added to said solution, dispersion or suspension prior to application of said high vacuum to enhance foam stability during secondary drying. 7. The method according to claim 6 wherein said solution, dispersion or suspension contains a protectant selected from the group consisting of a sugar, carbohydrate, polysaccharide, polymer, peptide, protein and a mixture thereof, wherein said protectant enhances the ability of the biologically active material to withstand drying and storage. 8. The method according to claim 1 wherein said process further includes the step of rehydrating said stable foam by contacting said foam with a suitable solvent. 9. The method according to claim 8 wherein said rehydration is performed at a termperature higher than the temperature in which the foam was stored prior to rehydration. 10. The method according to claim 9 wherein the temperature in which the foam was stored prior to rehydration is at least as high as ambient temperature. 11. The method according to claim 8 wherein said rehydration is performed at a temperature the same or lower than the temperature in which the foam was stored prior to rehydration. 12. The method according to claim 8 wherein the temperature in which the foam was stored prior to rehydration is lower than or equal to ambient temperature. 13. The method according to claim 8 wherein said solvent is an aqueous solution including a cryoprotectant. 14. The method according to claim 7 wherein said sugar is sucrose.
The present invention relates to novel peptides useful as anti-cancer agents. The compounds of the invention are of Formula I,A-B-D-E-F-G(I)A, B, D, and E are  alpha -amino acid residues. In one embodiment, F is an azacycloalkanecarboxylic acid residue. In this embodiment, G is a monovalent radical, for example, a hydrogen atom, an alkyl group, an aryl group, or a heteroaryl group. In another embodiment, F is an azacycloalkyl group and G is a heteroaryl group connected to F by a carbon-carbon bond. In another embodiment, the invention includes a method for treating cancer in a mammal, such as a human, comprising administering to the mammal an effective amount of a compound of Formula I in a pharmaceutically acceptable composition.
The invention discloses a Chinese herbal medicine for treating mammitis. The Chinese herbal medicine is characterized by being prepared from the following main raw materials in parts by weight: 20-30 parts of snakegourd fruit shells, 40-60 parts of dandelion, 15-25 parts of honeysuckle flower, 15-25 parts of fructus forsythiae, 15-25 parts of radix scutellariae, 5-15 parts of Chinese thorowax, 5-15 parts of akebiaquinata, 10-20 parts of pericarpium citri reticulatae viriole, 10-20 parts of uniflower swisscentaury roots and 10-20 parts of Chinese honeylocust spine. The invention also discloses a preparation method for the Chinese herbal medicine. The Chinese herbal medicine provided by the invention is easily obtained, good in curative effect, low in price and strong in pertinence. By adopting the medicine prescription, the Chinese herbal medicine provided by the invention is used for treating 108 patients with acute mastitis and cures 106 patients, and the effective rate on mammitis is up to 98% by now. The Chinese herbal medicine provided by the invention also has favorable curing effects on hyperplasia of mammary glands, swelling pain and lump existence, is superior to the conventional various treatment methods and medicines, and is high in security and free from toxic and side effects.
The invention relates to a cough candy with significant effects. The technology field of the invention relates to a TCM formula with cough-stopping curative effect. The main materials comprise honey, rock candy, white sugar and bulb of tendrilleat fritillary in a certain ratio of (10 to 35):(20 to 46):(30 to 60):(0.5 to 2.5). The materials are used to produce the cough candy with the common candy production line. The invention is characterized in that the cough sugar turns cough drug into candy, is convenient and interesting for patients to eat and has quite good effects. The invention has the advantages of the good tastes, natural materials and no negative effects, which is portable and suitable for both elders and children and quite efficient to treat cough caused by many kinds of diseases. Being very easy to achieve large scale industrial production, the invention has a good market prospect.
Abstinence from sexual practice among youth not only prevents infections, HIV and AIDS, and unplanned pregnancies but also promotes healthy sexual practices and positive youth development. The study aims to explore and describe interventions to improve healthy sexual practices among youth in Vhembe district, Limpopo province. The study utilized a descriptive cross-sectional design with a sample size of 531 determined by the selected formular through probability, simple random technique. Using structured questionnaires for data collection from the participants. Validity was ensured and content and face validity. Reliability was ensured. Data was analysed using SPSS version 28.0. Ethical consideration was ensured during the study. The study results showed that 57.4% of the respondents indicated that they do not discuss their choice of contraceptive with their sexual partner, 80.6% of the respondents indicated that unplanned pregnancy can be prevented by supplying contraceptives programs at clinics and school while 83.2% of the respondents revealed that programs linked with contraceptive services can help prevent unplanned pregnancy. The study highlights the lack of contraceptive choice discussions among sexual partners, exposing them to risks of STIs, HIV and AIDS, and teen pregnancy, urging for improved healthcare access.
Paeonol, a phenolic acid compound extracted from the Cortex Moutan, exhibits significant anti-inflammatory, antioxidant, and anti-apoptotic properties. This study aimed to investigate the effects of paeonol on neuroinflammation and depressive-like symptoms, and the underlying mechanisms in a mouse model of sepsis-associated encephalopathy (SAE) induced by lipopolysaccharide (LPS). To assess the therapeutic potential of paeonol in mice treated with LPS, behavioral assessments were conducted using the open-field test (OFT), tail suspension test (TST), and forced swimming test (FST), and quantitative PCR (qPCR), Western blot, and immunofluorescent staining were utilized to determine the expression levels of inflammatory molecules in the hippocampus in vivo and microglial cells in vitro. Our results revealed that paeonol significantly alleviated anxiety and depressive-like symptoms, as evidenced by improved activity in OFT, reduced immobility time in TST and FST, and decreased levels of inflammatory markers such as IL6, TNFα, and PFKFB3. Further in vitro experiments confirmed that paeonol downregulated the expression of pro-inflammatory molecules. A network pharmacology-based strategy combined with molecular docking and cellular thermal shift assay highlighted HIF1A as a potential target for paeonol. Similar anti-inflammatory effects of a HIF1A inhibitor were also observed in microglia treated with LPS. Furthermore, these effects were reversed by CoCl2, a HIF1A agonist, indicating the critical role of the HIF1A signaling pathway in mediating the therapeutic effects of paeonol. These findings highlight the potential of paeonol in modulating the HIF1A pathway, offering a promising therapeutic strategy for neuroinflammation in SAE.
Birth weight is a complex multifactorial trait relevant to health states and disease risks in later life. The placenta is essential for proper fetal growth and facilitates gas, nutrient, and waste exchange between the mother and developing fetus. How changes in placental DNA methylation affect fetal birth weight remains to be fully elucidated. In this study, we used whole-genome bisulfite sequencing and RNA sequencing to reveal a global map of DNA methylation and gene expression changes between the placentas of highest birth weight and lowest birth weight piglets in the same litters. The transcriptome analysis identified 1682 differential expressed genes and revealed key transcriptional properties in distinct placentas. We also identified key transcription factors that may drive the differences in DNA methylome patterns between placentas. The decrease in DNA methylation level in the promoter was associated with the transcriptional activation of genes associated with angiogenesis, extracellular matrix remodeling, and transmembrane transport. Our results revealed the regulatory role of DNA methylation in gene transcription activity leading to the differences in placental morphological structures and birth weights of piglets. These results could provide novel clues to clarify the underlying regulatory mechanisms of placental development and fetal growth.
Data submitted to the FDA was insufficient to establish efficacy in any childhood malignancy. 

Fludarabine phosphate was evaluated in 62 pediatric patients (median age 10, range 1 to 21) with refractory acute leukemia (45 patients) or solid tumors (17 patients). Limited pharmacokinetic data for fludarabine phosphate are available in children (ages 1 to 21 years). When fludarabine phosphate was administered as a loading dose over 10 minutes immediately followed by a 5-day continuous infusion, steady-state conditions were reached early. 

The fludarabine phosphate regimen tested for pediatric lymphocytic leukemia (ALL) patients was a loading bolus of 10.5 mg/m2/day followed by a continuous infusion of 30.5 mg/m2/day for 5 days. In 12 pediatric patients with solid tumors, dose-limiting myelosuppression was observed with a loading dose of 8 mg/m2/day followed by a continuous infusion of 23.5 mg/m2/day for 5 days. The maximum tolerated dose was a loading dose of 7 mg/m2/day followed by a continuous infusion of 20 mg/m2/day for 5 days. Treatment toxicity included bone marrow suppression. Platelet counts appeared to be more sensitive to the effects of fludarabine phosphate than hemoglobin and white blood cell counts. Other adverse events included fever, chills, asthenia, rash, nausea, vomiting, diarrhea, and infection. There were no reported occurrences of peripheral neuropathy or pulmonary hypersensitivity reaction.
The study will be a randomized, placebo-controlled, double-blinded clinical pivotal trial. Patients will be allocated in a ratio of 1:1 to the melatonin or placebo group. Patients will be stratified according to the type of surgery (lumpectomy or mastectomy). Randomization will be performed in blocks of randomized sizes. The study will be performed in the Department of Oncology, Rigshospitalet, Denmark.

Eligible patients with early breast cancer receive adjuvant radiation therapy over 15 to 30 daily fractions (5 fractions per week) of ionizing megavoltage photon radiation to a total of 40 - 60 Gy within 3-5 weeks according to the guidelines of the Danish Breast Cancer Cooperative Group. In this study, the patients will administer approximately 1 g of cream containing melatonin (25 mg/g) and dimethyl sulfoxide (DMSO) (150 mg/g) or a placebo cream topically twice daily on the irradiated skin area. The patients are scheduled to do this every day from the first to the last fraction of radiation therapy, including the days where they do not receive radiation therapy. The investigators have chosen placebo as the comparator due to it being safe and the most reasonable method of evaluating any effects of the intervention. On days where the patients receive radiation, the melatonin/DMSO or placebo cream will be applied no less than 2 hours prior to radiation. Throughout the study, the patients will meet with an investigator once weekly who will monitor compliance and assess outcomes.
Gelatin, widely employed in hydrogel dressings, faces limitations when used in high fluid environments, hindering effective material adhesion to wound sites and subsequently reducing treatment efficacy. The rapid degradation of conventional hydrogels often results in breakdown before complete wound healing. Thus, there is a pressing need for the development of durable adhesive wound dressings. In this study, 3-glycidoxypropyltrimethoxysilane (GPTMS) was utilized as a coupling agent to create gelatin-silica hybrid (G-H) dressings through the sol-gel method. The coupling reaction established covalent bonds between gelatin and silica networks, enhancing structural stability. Dopamine (DP) was introduced to this hybrid (G-H-D) dressing to further boost adhesiveness. The efficacy of the dressings for wound management was assessed through in-vitro and in-vivo tests, along with ex-vivo bioadhesion testing on pig skin. Tensile bioadhesion tests demonstrated that the G-H-D material exhibited approximately 2.5 times greater adhesion to soft tissue in wet conditions compared to pure gelatin. Moreover, in-vitro and in-vivo wound healing experiments revealed a significant increase in wound healing rates. Consequently, this material shows promise as a viable option for use as a moist wound dressing.
The invention relates to application of dihydrotanshinone I in preparing a medicament for treating liver cancer. The medicine takes dihydrotanshinone I as the only active ingredient. The medicament further comprises a pharmaceutically acceptable carrier selected from the group consisting of co-solvents, emulsifiers, fillers, binders, wetting agents, disintegrants, absorption enhancers and colorants. The invention also provides application of the composition of the dihydrotanshinone I and the lenvatinib in preparing medicines for treating liver cancer. The invention researches the drug effect of single or combined lenvatinib of the dihydrotanshinone I for treating liver cancer, and the result shows that the dihydrotanshinone combined with the lenvatinib effectively inhibits the growth of the liver cancer in vitro; the dihydrotanshinone I and the lenvatinib both have inhibitory effects on liver cancer cell proliferation to different degrees; the dihydrotanshinone I promotes apoptosis of the lenvatinib on liver cancer cells, can induce the occurrence of liver cancer cell apoptosis, and is concentrated in late apoptosis. And synergistically, lenvatinib increases the apoptosis rate of cells.
Familial multiple endocrine neoplasia type 1 (MEN1), familial hypocalciuric (or familial benign) hypercalcemia (FHH), hyperparathyroidism - jaw tumor syndrome (HPT-JT), other causes of familial isolated hyperparathyroidism (FIHP), and pseudohypoparathyroidism (PHP) are disorders of metabolism that are generally inherited in an autosomal dominant fashion. MEN1 is characterized by overgrowth and hyperfunction of the parathyroids, anterior pituitary and gastrointestinal endocrine tissue. MEN1, p15, p18, p21, and p27 are identified genes for MEN1- like states. FHH is characterized by a usually benign syndrome sometimes mistaken for typical primary hyperparathyroidism, which may result in unnecessary and unsuccessful parathyroid surgery. The CASR gene for the calcium-sensing receptor of the parathyroid cell is mutated in most FHH kindreds; a minority of kindreds with FHH have mutation of the GNA11 or AP2S1 gene. HPT-JT is a distinctive subtype of familial isolated hyperparathyroidism that has combinations of parathyroid adenoma, parathyroid cancer, jaw tumor, uterus tumor, kidney tumor and kidney cysts. It is caused by mutation of the CDC73/HRPT2 gene. PHP is characterized by parathyroid hormone resistance, and one form is associated with mutations in the gene encoding the alpha subunit of the stimulatory G protein. We are continuing to collect blood and tissue samples from affected and unaffected members of kindreds with known or suspected MEN1, FHH, HPT-JT, FIHP, PHP, and related disorders for the purpose of geneticanalysis and gene identification. In most cases, the procurement of specimens under this protocol will be at an off-site location. Samples will be processed for extraction of DNA and RNA.